Investigating the essential roles of Ubiquitin-like molecules and the Ubiquitin Proteasome System

UbiQ

UbiQ was founded by Huib Ovaa and Farid El Oualid from the Netherlands Cancer Institute together with Alfred Nijkerk, an experienced biotech entrepreneur. UbiQ has an active research line in proteasome activation and actively searches for pharmacological agents that target the ubiquitin proteasome system to treat neurodegenerative diseases (e.g. prion disease (BSE), Parkinson’s disease, Huntington’s and Alzheimer).

UbiQ

Projects

Proteasome activation to treat neurodegeneration.